Vital Biosciences Inc.: federal grants and contributions: 20 agreements; $2.7M value; 1 departments; 6 programs.
Assay record ASY-CA-11H6W481AE · Cite as: Assay Systems, “Vital Biosciences Inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/vital-biosciences-inc/
To quantify the strength and nature of the immune response to COVID-19 infection after recovery, the proposed serological tests will measure SARS-CoV-2-reactive IgG and IgM antibodies by rapidly adapting a next-generation immunoassay. By the end of the proposed project, all clinical validation tests required by Health Canada for expedited approval will be complete.
This project will cover the design and implementation of control systems to monitor the quality of reagents and various processes on our in vitro diagnostic platform. Having these systems in place will substantially mitigate the potential risk of patient harm by suppressing the results from any failed runs.
In-house capability to produce two integrated microfluidic discs (Clinical Chemistry, Immunoassay) that meet required specifications and reproducibility.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
There are numerous biomarkers present at low concentrations whose detection can provide valuable information pertaining an individual's health. Examples include but are not limited to; (i) antigens derived from SARS-CoV-2 whose presence in asymptomatic individuals is indicative of exposure or infection, (ii) cardiac troponin which when elevated is indicative of cardiac risk, (iii) various cytokine markers related to the "cytokine storm" seen in COVID-19 patients. NRC is seeking innovations which can be used in diverse settings by minimally trained users to assess a human sample for the presenc
The funding provided from the IAP program is to assist innovative, early stage small-and medium-sized enterprises that are unable to access existing COVID-19 business support.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
In the proposed project, we will conduct a formal analysis of hazards and risks for our point-of-care diagostic platform. This comprehensive evaluation of potential failure modes will be the foundation for a series of recommendations to mitigate failures or detect them when they occur.
This project will result in a scalable manufacturing process for proprietary ion-selective sensors for the quantification of blood electrolytes.
The proposed development of standardized quality control and fabrication protocols for our proprietary optical reporter particles will reduce batch variability and non-specific interactions, establishing greater control over the performance of Vital Biosciences’ diagnostic assays. By the end of the proposed project, all fabrication protocols, quality control documentation, and internal validation with a representative immunoassay will be complete; this work will support utility in our full menu of in vitro diagnostics technologies.
Reagent unitization and stabilization by lyophilization will enable the production of pre-dispensed and manipulatable reagents in assay cartridges that are shelf stable at room temperature. This will simplify assay setup for end users, while increasing assay precision and reliability and decreasing the risk of accidental sample contamination. The proposed project will examine various lyophilization protocols and combinations of possible excipients to generate dried reagents in uniform beads that preserve reagent activity and can readily be reconstituted in buffer during use. The project will a
Clinical chemistry assays each come with different canonical protocols. Our goal is to reduce the large patient sample and reagent volumes required with traditional assay protocols, and run a large menu in parallel on a compact microfluidic disc. The Graduate’s work on assay development will enable a significant reduction in blood sample volumes, automated assay operation, and faster turnaround times for end users.
This project will cover various verification and validation activities for prototype devices as Vital moves towards its first commercial launch.
This project will cover various process development activities for liquid and lyophilized reagents as Vital moves towards its first commercial launch.
This project will cover development activities for enhancing instrument prototype design as Vital moves towards its first commercial launch.
This project will cover various process development activities for liquid and lyophilized reagents as Vital moves towards its first commercial launch.
Hire of an Assay Development and Integration Technician.
The purpose of this CanExport Innovation agreement is to support Canadian organizations to carry out activities related to pursuing opportunities that would lead to establishing new collaborative Research and Development (R&D) partnerships between the Recipient and foreign organizations in order to support R&D on the Recipient’s technology and advance its commercialization.
Support to enhance the Firm’s IP strategy
Participation in the Canadian Life Sciences co-innovation mission to Japan – October 6 to 10, 2025. Delegation led by the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to explore the Japanese market and to develop international partnerships and potential project ideas under the Japan Program. In Partnership with the Trade Commissioner Service Canadian Technology Accelerator (TCS CTA), and Deep Tech Canada, the Canadian delegation will also receive support for their international business and market-entry strategies, as well as get introductions to other
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.